EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

The 7-Methylguanosine (m7G) methylation METTL1 acts as a potential biomarker of clear cell renal cell carcinoma progression

Yi Liu, Yanji Zhan, Jiao Liu, Zhengze Shen, Yudong Hu, Ling Zhong, Yuan Yu, Bin Tang, Jing Guo

Translational Oncology · 2025-01 · 51 · 102202

DOI: 10.1016/j.tranon.2024.102202 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Translational Oncology, 2025-01. Verfasst von Yi Liu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Second Affiliated Hospital, Chongqing Medical University, Chongqing, 400010, China; The 3rd Affiliated Hospital, Chengdu Me…. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Clear cell renal cell carcinoma (ccRCC) is the most common subtype of renal cancer. 7-Methylguanosine (m7G), one of the most prevalent RNA modifications, has been reported to play an important role in ccRCC progression; however, the specific regulators of m7G modification that are involved in this function remain unclear. This study aimed to explore the correlation between regulators of m7G methylation and ccRCC progression using unsupervised machine learning methods. METHODS: Transcriptome and clinical data of ccRCC were retrieved from The Cancer Genome Atlas (TCGA) database to identify differentially expressed m7G-related genes associated with the overall survival of patients with ccRCC. To construct and validate a prognostic risk model, TCGA dataset samples were divided into training and test sets. A multiple-gene risk signature was constructed using least absolute shrinkage and selection operator Cox regression analysis, and its prognostic significance was assessed using Cox regression and survival analyses. Finally, immunohistochemistry was performed to verify the prognostic significance of this signature. RESULTS: In total, 537 patients with ccRCC were included in this study. We found that 26 m7G RNA methylation regulators that were significantly differentially expressed. Univariate and multifactorial Cox regression analyses revealed that METTL1 expression was associated with ccRCC progression. CONCLUSIONS: METTL1 associated with m7G may serve as a potential biomarker for ccRCC prognosis and diagnosis. Moreover, it may affect the prognosis of ccRCC by regulating the tumor immune microenvironment, providing a potential therapeutic target for immunotherapy. These results provide a new perspective on the role of M7G-related RNAs in ccRCC pathogenesis.

Schlagwörter

Stichwörter der Autor:innen

7-methylguanosine (m7G)Clear cell renal cell carcinomaMETTL1PrognosisTumor immune microenvironment

Autor:innen und Institutionen

  • Department of Nephrology, Second Affiliated Hospital, Chongqing Medical University, Chongqing, 400010, China; The 3rd Affiliated Hospital, Chengdu Medical College, Chengdu Pidu District People's Hospital, Chengdu, 61173…
  • Department of Nephrology, Second Affiliated Hospital, Chongqing Medical University, Chongqing, 400010, China.
  • Department of Nephrology, Second Affiliated Hospital, Chongqing Medical University, Chongqing, 400010, China; Department of Nephrology, Wushan County People's Hospital of Chongqing, 404700, China.
  • Department of Pharmacy, Yongchuan Hospital of Chongqing Medical University, Chongqing, 402160, China.
  • Department of Nephrology, Second Affiliated Hospital, Chongqing Medical University, Chongqing, 400010, China. Electronic address: tangbin@hospital.cqmu.edu.cn.
  • Radiation Oncology Center, Chongqing University Cancer Hospital, Chongqing University, Chongqing 400030, China. Electronic address: guojingcoco@cqu.edu.cn.

Zitieren

APA

Liu, Y., Zhan, Y., Liu, J., Shen, Z., Hu, Y., Zhong, L., Yu, Y., Tang, B., & Guo, J. (2025). The 7-Methylguanosine (m7G) methylation METTL1 acts as a potential biomarker of clear cell renal cell carcinoma progression. Translational Oncology, 51, 102202. https://doi.org/10.1016/j.tranon.2024.102202

Vancouver

Liu Y, Zhan Y, Liu J, Shen Z, Hu Y, Zhong L, et al. The 7-Methylguanosine (m7G) methylation METTL1 acts as a potential biomarker of clear cell renal cell carcinoma progression. Translational Oncology. 2025;51:102202. doi:10.1016/j.tranon.2024.102202

BibTeX
@article{Liu2025,
  author = {Liu, Yi and Zhan, Yanji and Liu, Jiao and Shen, Zhengze and Hu, Yudong and Zhong, Ling and Yu, Yuan and Tang, Bin and Guo, Jing},
  title = {The 7-Methylguanosine (m7G) methylation METTL1 acts as a potential biomarker of clear cell renal cell carcinoma progression},
  journal = {Translational Oncology},
  year = {2025},
  volume = {51},
  pages = {102202},
  doi = {10.1016/j.tranon.2024.102202}
}
Kostenlos starten →